PD-1 inhibition in advanced myeloproliferative neoplasms
Gabriela Hobbs(Massachusetts General Hospital), John Mascarenhas(Tisch Hospital), Camelia Iancu‐Rubin(Tisch Hospital), Molly Macrae(Massachusetts General Hospital), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Erin Moshier, Martha Wadleigh(Dana-Farber Cancer Institute), Hetal D. Marble(Massachusetts General Hospital), Nina Bhardwaj(Mount Sinai Hospital), Cansu Cimen Bozkus, Richard M. Stone(Dana-Farber Cancer Institute), Tina T. Som(Harvard University), Nicole Zubizarreta(Icahn School of Medicine at Mount Sinai), Michal Bar‐Natan(NewYork–Presbyterian Hospital), Siraj M. El Jamal(Rutgers, The State University of New Jersey), Kathryn Johnson(Harvard University), Mikaela Dougherty(Icahn School of Medicine at Mount Sinai), Julia Foster(Harvard University), Lonette Sandy(Icahn School of Medicine at Mount Sinai)
Cited by 43
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k